Boston Scientific Corp. stock (US10117L1017): Wolfe Research downgrade in focus as shares trade near recent highs

Boston Scientific Corp. shares remained in the spotlight on the New York Stock Exchange after Wolfe Research lowered its rating on the S&P 500 healthcare stock on 05/29/2026, even as the company continues to attract institutional interest and trades close to its recent highs, according to recent filings and research updates from the United States.

Wolfe Research cut its stance on Boston Scientific to "Peer Perform" from "Outperform" in a note dated 05/29/2026, according to a report summarized by Fintel that highlighted the change in the research house's view on the stock.Fintel as of 05/29/2026 While the note did not change a published target price in that summary, it underscores a more cautious stance on near-term upside following a strong run in the shares in 2025 and early 2026.

Against this backdrop, Boston Scientific's stock continues to trade actively on its home US market. The stock traded at around USD 70 on 05/31/2026 on the NYSE under the ticker BSX, based on recent exchange data.NYSE as of 05/31/2026 The company is headquartered in Marlborough, Massachusetts, and is one of the larger US-based medical technology names within the S&P 500 universe. For German investors, the shares are also available via off-exchange venues such as Tradegate in euros, although liquidity is typically highest in the United States.

Institutional positioning has remained active around the stock. A recent filing summary reported that Nomura Asset Management Co. Ltd. increased its position in Boston Scientific during the fourth quarter of the prior fiscal year, signaling continued interest from Japanese institutional investors.MarketBeat as of 05/31/2026 In a separate fourth-quarter disclosure, MUFG Securities EMEA plc lifted its stake in the company by more than 1,000%, highlighting that global financial institutions continue to see the stock as a relevant exposure to the medical devices segment.MarketBeat as of 05/31/2026

Alongside the change at Wolfe Research, the broader analyst community has remained supportive in aggregate. MarketBeat data as of 05/31/2026 indicates that Boston Scientific carries a "Moderate Buy" consensus rating from Wall Street, with an average target price of USD 87.46, suggesting room for upside relative to recent trading levels if those expectations materialize.MarketBeat as of 05/31/2026 Bank of America, for example, previously adjusted its price objective on the stock from USD 105.00 to USD 68.00 while maintaining a "buy" rating, illustrating that even supportive houses can recalibrate expectations as the share price and earnings profile evolve over time.MarketBeat as of 02/02/2024

From a capital allocation perspective, Boston Scientific has also kept shareholder returns on the agenda. The company declared that its board approved a stock repurchase program on 05/18/2025 authorizing up to USD 5.0 billion of share buybacks, according to a filing summary, providing management with flexibility to return capital and offset dilution from share-based compensation in the coming years.MarketBeat as of 05/18/2025 While the pace of repurchases can fluctuate with cash flow needs and acquisition opportunities, the authorization is one component of the broader equity story closely watched by US investors.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Boston Scientific Corp.: core business model

Boston Scientific focuses on minimally invasive medical technologies, with sales primarily generated from cardiovascular, structural heart, endoscopy, urology and neuromodulation devices used by hospitals and physicians worldwide.

Chart technicals and 52-week range

From a technical perspective, Boston Scientific's share price has been trading near the upper end of its 52-week range in recent weeks, reflecting the strong performance of US medical technology stocks and ongoing investor interest in the sector.MarketWatch as of 05/31/2026 Over the past 12 months, the stock's 52-week low and high on the NYSE have framed the risk-reward profile for traders, with the price currently closer to the high than the low, according to major financial data providers that track intraday and historical quotes.Nasdaq as of 05/31/2026

Technical indicators such as moving averages are also closely watched by market participants. As of late May 2026, Boston Scientific has been trading above its 200-day moving average, a level many US investors regard as a proxy for long-term trend support, while shorter-term averages have shown a steady upward slope in line with the stock's broader positive trajectory over the past quarters.TradingView as of 05/31/2026 Momentum indicators like the relative strength index (RSI) have periodically approached overbought territory but have not consistently stayed there, indicating ongoing two-way trading interest rather than an extreme one-sided market.

Conclusion

The key driver for Boston Scientific Corp. on 05/29/2026 was Wolfe Research's downgrade to "Peer Perform", which temporarily tempered sentiment after a period of strong share price gains and active institutional participation in the United States. At the same time, consensus data continue to show a broadly favorable analyst view with a "Moderate Buy" stance and an average target price above current levels, and the stock's position near the top of its 52-week range highlights how the market is weighing robust fundamentals against valuation and technical considerations.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.